There is a system for collecting safety information about medicines and devices in the UK, it is open to the public, it takes a few minutes, and almost nobody in the cosmetic sector uses it. This article explains what it is for and why using it matters even when you are also complaining elsewhere.
What the Yellow Card scheme is
The Yellow Card scheme is run by the MHRA. It collects reports of suspected adverse drug reactions and of adverse incidents involving medical devices. Reports come from healthcare professionals, from manufacturers and from members of the public, and the patient reporting route is deliberate rather than incidental.
The data feeds signal detection. Patterns across many reports can identify a problem with a particular product, batch or device type that no individual case would show. That is the point: your single report is not expected to prove anything on its own.
What to report in this sector
Medicines. Suspected adverse reactions to botulinum toxin products, to local anaesthetics, to hyaluronidase and to any other prescription only medicine used in your treatment. Effects spreading beyond the intended area, unexpected weakness, allergic reactions and unusually prolonged effects are all reportable.
Devices. Adverse incidents involving dermal fillers, threads, energy based devices and other equipment. This includes nodules, granulomas, infections associated with a product, migration, and product that behaved unexpectedly.
Suspected falsified or unlicensed product. If you have reason to think the product used was counterfeit, unlicensed or obtained outside the lawful supply chain, the MHRA wants to know. This is a serious enforcement matter and one where patient reports have real value.
What you are entitled to at this stage
- To report a suspected adverse reaction or device incident directly to the MHRA, as a patient, without a clinician's involvement.
- To report on suspicion, without needing to prove that the product caused the problem.
- To a copy of your records including the product name and batch number, under a subject access request.
- To pursue a Yellow Card report and a regulatory complaint and a claim at the same time.
- To report suspected falsified or unlicensed product to the MHRA.
A Yellow Card report is not a complaint about a practitioner and is not sent to them.
You do not need to be certain
This is the point that stops most people reporting. The scheme collects suspected reactions and incidents. You are not asserting causation, you are recording a temporal and clinical association and letting the regulator's analysts assess it alongside everything else they hold.
Nor do you need to have exhausted anything else first. A Yellow Card report is not a complaint about the practitioner, it does not go to them, and it does not affect any other route you are pursuing.
What information to have ready
- The product name, and the batch or lot number if you have it.
- The date of treatment and the date the problem started.
- The area treated and the amount used, if you know it.
- A description of what happened and how it developed.
- Any treatment you received for the problem.
- Your age, sex and any relevant medical history or medication.
The batch number is the item most often missing, which is why we suggest recording it at the time of treatment rather than trying to obtain it afterwards. If you do not have it, request your records: it should be there. If it is not recorded anywhere, that itself is a record keeping failure worth raising with the practitioner's regulator.
A clinic that cannot tell you the product name or batch number afterwards. Recording what was injected is basic practice, and its absence suggests either poor record keeping or a supply chain the clinic would rather not document.
Why it matters more here than elsewhere
Cosmetic procedures sit outside the routine reporting culture of clinical medicine. A hospital has systems that capture incidents; a small aesthetic practice frequently does not. Patients often assume that a complication was their own bad luck, or feel that they cannot complain about something they elected to have. The result is that the surveillance data for this sector is thinner than for almost any comparable area of practice.
That thinness has consequences. It weakens the evidence available to regulators considering whether to act on a product. It weakens the case for the licensing scheme this sector has been debating for years. And it means that the true complication picture for widely used products is not well described in public data.
This is one of the few areas where an individual patient can materially improve the information available to everyone else, at the cost of ten minutes.
Do the other things as well
Reporting to the MHRA does not replace anything. If a registered professional was involved and something went wrong clinically, raise it with their regulator. If you want money back, that is a consumer or negligence route. If the marketing misled you, that is the ASA. The routes are set out in how to complain and to whom, and they run in parallel rather than in sequence.